Work

A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4654

Authors: Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin M. Posadas, Michael Roger Harrison, Justine Yang Bruce, Evan Y. Yu, Steve Y. Cho, Gregory E. Wilding, Gerald J. Fetterly, David G. Hangauer, Min-Fun Rudolf Kwan, Lyn M. Dyster, Michael Anthony Carducci

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Cedars-Sinai Medical Center, Duke University, Duke Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Fred Hutch Cancer Center, University at Buffalo, State University of New York, Roswell Park Comprehensive Cancer Center, Athenex (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2600744764

Cites:

Cited by: 1

Related to: 10